Moroncini (università Marche), Jak inibitore molecole molto promettenti anche per trattamento Les

adnkronos

(Adnkronos) - “Nuova classe di immunomodulatori per via orale bloccano uno specifico enzima che attiva diversi recettori cellulari. Pur riconoscendo un bersaglio molecolare specifico in realtà sono antiinfiammatori modulatori ad ampio spettro. Il mio centro è impegnato in un trial clinico multicentrico per  se abbiano nel Lupus eritematoso sistemico un’efficacia pari a quella che hanno già dimostrato in altre malattie per le quali sono autorizzate, come l’artrite reumatoide o l’artrite psoriasica. Attendiamo con ansia esito sperimentazioni”.

Transcript

00:00Lupus is a systemic disease, immuno-mediated, also called autoimmune disease, and there are, let's say, various subtypes.

00:16With a single name, we include various types of diseases.

00:20Like all immuno-mediated diseases, it is a heterogeneous disease, so we can have limited skin forms,

00:25we can have mainly articulated forms, forms in which the middle bone is also involved,

00:29other forms in which the kidney or other internal organs are involved, such as the lungs or the heart.

00:34The neurological system can also be involved, even the central nervous system.

00:39So an extremely pleiotropic disease, heterogeneous, in which these various organs or tissues can be involved

00:46either separately or in some of the most dangerous forms, even all together.

00:52And so the difficulty of the clinic is to interpret exactly the subtype of disease

00:58and understand in advance when certain organs or tissues, perhaps initially not involved,

01:03may be able to become part of the disease picture.

01:06Jack inhibitors are a new class of immuno-modulators, let's call them that.

01:11They are small molecules that can be taken by mouth and that specifically block a certain enzyme,

01:17namely the Janus kinase, Jack, which is in fact an activator of certain receptors.

01:23Our cells have a sort of antenna on their surface that receives inflammatory signals.

01:29Well, these small molecules are able to block many receptors

01:34that translate many different inflammatory molecules into these cells.

01:39From this point of view, they are very interesting molecules,

01:42so even recognizing a specific molecular target,

01:45they are actually able to block a wide range of inflammatory signals.

01:51So they are large-spectrum immuno-modulating anti-inflammatories.

01:55We are not yet authorized to use them, especially in lupus, because they are not yet approved,

02:00but my center is committed to a multi-centric clinical trial,

02:04precisely to experiment with the use of these molecules,

02:07in particular one of these, lupa-dacitinib,

02:10precisely to verify whether these molecules have an equal effectiveness in lupus

02:14to those they already have in other diseases for which they are authorized,

02:17such as rheumatoid arthritis or psoriasis arthritis.

02:20So we look forward to the success of this experiment

02:24in order to be able to implement it also in our patients affected by LES.

Category

Transcript

Be the first to comment

Recommended